XXcelerate Resources
1.
All of Us Research Program. All of Us Research Program [Website]. National Institutes of Health, https://allofus.nih.gov/
2.
Andrews, D., & Collins, L. (2024). Sex-specific responses to lecanemab and donanemab. Alzheimer’s & Dementia: Translational Research & Clinical Interventions., https://doi.org/10.1002/trc2.70155
3.
Andrews, D., Ducharme, S., Chertkow, H., Sormani, M. P., Collins, D. L., & the Alzheimer’s Disease Neuroimaging Initiative. (2024). The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effect (Version 1). medRxiv, https://doi.org/10.1101/2024.07.11.24310278
4.
Andrews, Daniel et al. (2025). “The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effect.” Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 21,1: e14467. https://pmc.ncbi.nlm.nih.gov/articles/PMC11779744/
5.
Cassella, C. (25 Mar. 2025). Men and women may respond differently to latest Alzheimer’s drugs. ScienceAlert, https://www.sciencealert.com/men-and-women-may-respond-differently-to-latest-alzheimers-drugs
6.
Centers for Disease Control and Prevention. (25 Oct. 2025). All of Us Reports and Publications Database. Public Health Genomics & Precision Health Knowledge Base, https://phgkb.cdc.gov/PHGKB/allOfUsPublicationStartPage.action
7.
Chhibba, Taruna; Wong, Emily C.L.b; Reinisch, Walterc; Targownik, Laurad; Narula, Neerajb. (Jun. 2024). Comparing the efficacy of vedolizumab between males and females: a post-hoc analysis of GEMINI-1 and VARSITY. European Journal of Gastroenterology & Hepatology, 36(6):p 704-711. https://doi.org/10.1097/MEG.0000000000002759
8.
Jairath, Vipul et al. ENTERPRET: A Randomized Controlled Trial of Vedolizumab Dose Optimization in Patients With Ulcerative Colitis Who Have Early Nonresponse. Clinical Gastroenterology and Hepatology, 22(5), 1077–1086.e13. https://www.cghjournal.org/article/S1542-3565(23)00912-6/fulltext
9.
European Society of Cardiology. (30 Aug. 2025). Beta-blockers did not reduce cardiovascular events in selected heart attack patients in the REBOOT trial [Press release]. The ESC Press Office, https://www.escardio.org/The-ESC/Press-Office/Press-releases/Beta-blockers-did-not-reduce-cardiovascular-events-in-selected-heart-attack-patients-in-the-REBOOT-trial
10.
Feagan, B. G., Rutgeerts, P., Sands, B. E., Hanauer, S. B., Colombel, J.-F., & GEMINI 1 Study Group. (2013). Vedolizumab as induction and maintenance therapy for ulcerative colitis. The New England Journal of Medicine, 369(8), 699-710. https://doi.org/10.1056/NEJMoa1215734
11.
Framingham Heart Study. “About the Framingham Heart Study.” Framingham Heart Study, Boston University & National Heart, Lung, and Blood Institute., https://www.framinghamheartstudy.org/fhs-about/
12.
Fuentealba, M., Rouch, L., Guyonnet, S., de Souto Barreto, P., Vellas, B., Andrieu, S., Lemaitre, J.-M., Furman, D., & colleagues. (2025). A novel blood-based epigenetic clock for intrinsic capacity predicts mortality and is associated with clinical, immunological, and lifestyle factors. Nature Aging, https://www.nature.com/articles/s43587-025-00883-5
13.
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J.-F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., Rutgeerts, P., & ACCENT I Study Group. (2002). Maintenance infliximab for Crohn’s disease: The ACCENT I randomized trial. The Lancet, 359(9317), 1541–1549. https://doi.org/10.1016/S0140-6736(02)08512-4
14.
Ikram, M. Arfan et al. (2017). “The Rotterdam Study: 2018 update on objectives, design and main results.” European Journal of Epidemiology, 32(9): 807–850. https://pmc.ncbi.nlm.nih.gov/articles/PMC5662692/
15.
McGill University, Andrews, D., & Collins, L. (2024). Sex differences in treatment effects of lecanemab and donanemab: A simulation study. medRxiv, https://www.medrxiv.org/content/10.1101/2024.07.11.24310278v1.full.pdf
16.
Mente, Andrew et al. (2023). “Diet, cardiovascular disease, and mortality in 80 countries.” European Heart Journal, 44(28): 2560–2579. https://pubmed.ncbi.nlm.nih.gov/37414411/
17.
National Heart, Lung, and Blood Institute. “Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).” U.S. Department of Health and Human Services, https://www.nhlbi.nih.gov/science/antihypertensive-and-lipid-lowering-treatment-prevent-heart-attack-trial-allhat
18.
Nurses’ Health Study. ((n.d.)). The Nurses’ Health Study and Nurses’ Health Study II: Among the largest investigations into the risk factors for major chronic diseases in women. Harvard T.H. Chan School of Public Health & Brigham and Women’s Hospital, https://nurseshealthstudy.org/
19.
Peng, Jingyi et al. (2025). “Global, regional and national burden of inflammatory bowel disease in females from 1990 to 2021: an analysis of the global burden of disease study 2021.” Frontiers in Global Women's Health, 6, 1580451. https://pmc.ncbi.nlm.nih.gov/articles/PMC12158981/
20.
RECOVERY Trial. (2025). RECOVERY Trial: identifying treatments that may be beneficial for people hospitalised with pneumonia. University of Oxford, https://www.recoverytrial.net/
21.
Rosselló, X., Raposeiras-Roubin, S., Latini, R., Domínguez-Rodríguez, A., Barrabés, J. A., Sánchez, P. L., Fernández-Vázquez, F., Pascual-Figal, D., De la Torre Hernández, J. M., & REBOOT-CNIC Investigators. (2025). Beta-blockers after myocardial infarction: Effects according to sex in the REBOOT trial. European Heart Journal, https://doi.org/10.1093/eurheartj/ehaf673
22.
Rosselló, X., Raposeiras-Roubin, S., Latini, R., Domínguez-Rodríguez, A., Barrabés, J. A., Sánchez, P. L., Anguita, M., Fernández-Vázquez, F., Pascual-Figal, D., De la Torre Hernández, J. M., Ferraro, S., Vetrano, A., Pérez-Rivera, J. A., Prada-Delgado, O., Escalera, N., Staszewsky, L., Pizarro, G., Agüero, J., Pocock, S., & Ibáñez, B. (2022). Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT). European Heart Journal – Cardiovascular Pharmacotherapy, 8(3), 291–301. https://doi.org/10.1093/ehjcvp/pvab060
23.
Rutgeerts, Paul et al. (2005). “Infliximab for induction and maintenance therapy for ulcerative colitis.” The New England Journal of Medicine, 353(23): 2462–2476. https://pubmed.ncbi.nlm.nih.gov/16339095/
24.
Sands, B. E., Peyrin-Biroulet, L., Loftus, E. V., Jr., Danese, S., Colombel, J.-F., Törüner, M., Jonaitis, L., Abhyankar, B., Chen, J., Rogers, R., & Bornstein, J. D. (2019). Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. New England Journal of Medicine, 381(13), 1215–1226. https://doi.org/10.1056/NEJMoa1905725
25.
Stoiko, R. R., & Strough, J. (2018). His and Her Retirement: Effects of Gender and Familial Caregiving Profiles on Retirement Timing. The International Journal of Aging and Human Development, 89(2), 131–150. https://journals.sagepub.com/doi/abs/10.1177/0091415018780009
26.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. (2002). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The ALLHAT trial. JAMA, 288(23), 2981–2997. https://doi.org/10.1001/jama.288.23.2981
27.
Ubago-Guisado, Esther et al. (2021). “Evidence Update on the Relationship between Diet and the Most Common Cancers from the European Prospective Investigation into Cancer and Nutrition (EPIC) Study: A Systematic Review.” Nutrients, 13(10), 3582. https://pmc.ncbi.nlm.nih.gov/articles/PMC8540388/
28.
UK Biobank. ((n.d.)). UK Biobank: Improving the health of future generations, https://www.ukbiobank.ac.uk/
29.
Wei Zheng, Wong-Ho Chow, Gong Yang, Fan Jin, Nathaniel Rothman, Aaron Blair, Hong-Lan Li, Wanqing Wen, Bu-Tian Ji, Qi Li, Xiao-Ou Shu, Yu-Tang Gao. (2005). “The Shanghai Women's Health Study: Rationale, Study Design, and Baseline Characteristics.” American Journal of Epidemiology, 162(11): 1123–1131. https://academic.oup.com/aje/article-abstract/162/11/1123/185210
30.
White, Peter D et al. (2015). “The planning, implementation and publication of a complex intervention trial for chronic fatigue syndrome: the PACE trial.” BJPsych Bulletin, 39(1): 24–27. https://pmc.ncbi.nlm.nih.gov/articles/PMC4495840/